CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Ixazomib +2 moredrug
Likely dose
Ixazomib 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02412228
NCT02412228Phase 2Completed
CompareCT.gov

BrUOG 299: Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.

John L. Reagan·interventional·Posted Apr 9, 2015·Updated Oct 15, 2025

In Brief

A Phase 2 clinical trial evaluating Ixazomib, Cyclophosphamide, and 1 other intervention for Multiple Myeloma. Completed, enrolled 12 participants across 3 sites.

Detailed Summary

The goal of this proposal is to develop a more effective and better tolerated regimen. Ixazomib appears to have greater activity than bortezomib with less peripheral neuropathy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsRhode Island Hospital, The Miriam Hospital, Memorial Hospital of Rhode Island

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 9, 2015
Enrollment StartAug 1, 2015
Primary CompletionMar 29, 2019
Study CompletionNov 9, 2023
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 11.2 years ago

Interventions

Ixazomibdrug

Cycle 1: Ixazomib: 4mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Maintenance: Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years

Cyclophosphamidedrug

Cycle 1: Cyclophosphamide: 50 mg/day continuous daily Cycles 2-6: Cyclophosphamide: 50 mg/day continuous daily

Dexamethasonedrug

Cycle 1: Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18